Merck
CN
Search Within
Document Type

212-017-2

Applied Filters:
Keyword:'212-017-2'
Showing 1-4 of 4 results for "212-017-2" within Technical Documents
Unlocking the Mystery of Cancer: Do the Mutant p110α Subunits of PI3-Kinase Hold the Key?
(5 x 384 assay points) 33-017 Wortmannin (PI3 Kinase inhibitor) 12-338 mTOR (1362-end), active 14-770 Anti-PI3 Kinase, p85 06-195 Anti-PI3 Kinase, p85, N-SH3, clone AB6 05-212 Anti-PI3 Kinase, p110α 07-
MAPK: Antibodies, Proteins, Kits, siRNA and Reagents
resistant to IGFBPs) CULT 25 µg 01-189 IGF-I CULT 25 µg 01-208 IGF-I, biotin conj. WB HPLC 2 µg 01-212 Insulin-like Growth Factor-I, recombinant human Pur 100 µg GF006 Insulin-like Growth Factor-II
Cytoskeletal Signaling Antibodies, Reagents and Kits
338 Assay PI 3-Kinase HTRF® Assay KA 1 plate 33-016 PI 3-Kinase HTRF Assay KA 5 plates 33-017 PIKE Polyclonal Antibody PIKE-L/S H R WB IP APur Rb IgG 200 µg 07-675 PKA Monoclonal Antibody
Manual Spectroquant NOVA 30
– 75.0 mg/l Mg Phthalein purple 159 Manganese Cell Test* 100816 0.10 – 5.00 mg/l Mn Formaldoxime 017 Nickel Cell Test* 114554 0.10 – 6.00 mg/l Ni Dimethylglyoxime 057 Nickel Baths 10 – 120 g/l Ni Inherent